Prevest Denpro

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE0GAO01018
  • NSEID:
  • BSEID: 543363
INR
361.60
-6.4 (-1.74%)
BSENSE

Jun 12, 12:46 PM

BSE+NSE Vol: 3200

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.2 k (9.59%) Volume

Shareholding (Mar 2026)

FII

0.65%

Held by 1 FIIs

DII

0.77%

Held by 0 DIIs

Promoter

73.60%

Why is Prevest Denpro Ltd falling/rising?

12-Jun-2026

As of 11-Jun, Prevest Denpro Ltd's stock price is at 368.00, down 1.21%, and has significantly underperformed against the Sensex over various time frames, with a year-to-date decline of 25.13%. The stock is also trading below all moving averages, indicating a bearish trend and decreased investor confidence.

As of 11-Jun, Prevest Denpro Ltd's stock price is falling, currently at 368.00, which reflects a decrease of 4.5 points or 1.21%. The stock has underperformed compared to the benchmark Sensex, which has only declined by 0.71% over the past week. Over the last month, Prevest Denpro's stock has dropped by 10.79%, significantly more than the Sensex's 2.87% decline. Year-to-date, the stock is down 25.13%, while the Sensex has only fallen by 13.36%. <BR><BR>Today's performance indicates a notable underperformance against its sector, with a decline of 4.07%. The stock reached an intraday low of Rs 364.2, marking a decrease of 2.23%. Additionally, Prevest Denpro is trading below its moving averages across all time frames (5-day, 20-day, 50-day, 100-day, and 200-day), suggesting a bearish trend. <BR><BR>Investor participation has also decreased, with a delivery volume of 3.4k on June 10, which is down 42.18% compared to the 5-day average. This decline in trading activity further indicates a lack of confidence among investors. Overall, these factors contribute to the falling stock price of Prevest Denpro Ltd.

View full answer

What does Prevest Denpro do?

11-Jun-2026

Prevest Denpro Ltd is a micro-cap manufacturer of dental materials, incorporated in 1999, with recent net sales of 19 Cr and a net profit of 6 Cr as of March 2026. The company has a market cap of INR 460 Cr and key financial metrics include a P/E ratio of 22.00 and a return on equity of 16.42%.

Overview:<BR>Prevest Denpro Ltd is a leading manufacturer of dental materials in the healthcare services industry, categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on May 05, 1999, with the Registrar of Companies in Jammu & Kashmir. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 19 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 6 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 460 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 22.00 <BR>Industry P/E: 92 <BR>Dividend Yield: 0.27% <BR>Debt Equity: -0.65 <BR>Return on Equity: 16.42% <BR>Price to Book: 3.54 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

View full answer

How big is Prevest Denpro?

11-Jun-2026

As of 10th June, Prevest Denpro Ltd has a market capitalization of 460.00 Cr and reported net sales of 71.81 Cr and net profit of 20.49 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Prevest Denpro Ltd has a market capitalization of 460.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 71.81 Cr, while the sum of Net Profit for the same period is 20.49 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 105.57 Cr, and Total Assets amount to 112.53 Cr.

View full answer

Who are in the management team of Prevest Denpro?

11-Jun-2026

The management team of Prevest Denpro includes Atul Modi (Chairman & Managing Director), Namrata Modi (Whole Time Director & CFO), Sai Kalyan Surapaneni (Executive Director), Niharika Modi (Non-Executive Director), Nikhil Shrikant Bobade (Independent Non-Executive Director), Sudeep Haralakatte Murthy (Independent Non-Executive Director), Vaibhav Munjal (Executive Director), and Pardeep Gandotra (Independent Non-Executive Director). They oversee the company's operations and strategic direction.

The management team of Prevest Denpro includes the following individuals:<BR><BR>1. **Atul Modi** - Chairman & Managing Director<BR>2. **Namrata Modi** - Whole Time Director & CFO<BR>3. **Sai Kalyan Surapaneni** - Executive Director<BR>4. **Niharika Modi** - Non-Executive Director<BR>5. **Nikhil Shrikant Bobade** - Independent Non-Executive Director<BR>6. **Sudeep Haralakatte Murthy** - Independent Non-Executive Director<BR>7. **Vaibhav Munjal** - Executive Director<BR>8. **Pardeep Gandotra** - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

View full answer

Who are the peers of the Prevest Denpro?

11-Jun-2026

Prevest Denpro's peers include 3B Blackbio, Health X Platfor, Hemant Surgical, Take Solutions, Nureca, Jeevan Scientific, and QMS Medical. Hemant Surgical leads in 1-year returns at 278.57%, while 3B Blackbio has the lowest at -23.84%, with Prevest Denpro slightly better at -22.92%.

Peers: The peers of Prevest Denpro are 3B Blackbio, Health X Platfor, Hemant Surgical, Take Solutions, Nureca, Jeevan Scienti., and QMS Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at 3B Blackbio and Health X Platfor, while Average management risk is found at Hemant Surgical and QMS Medical, and the rest have Below Average management risk. Growth is Good at Hemant Surgical, Average at Health X Platfor, and Below Average at 3B Blackbio, Take Solutions, Nureca, Jeevan Scienti., and QMS Medical. Excellent capital structure is noted for 3B Blackbio and Health X Platfor, Good for Nureca and Hemant Surgical, while Average is seen at Jeevan Scienti. and QMS Medical, and Below Average at Take Solutions.<BR><BR>Return Snapshot: Hemant Surgical has the highest 1-year return at 278.57%, while 3B Blackbio has the lowest at -23.84%, with Prevest Denpro's 1-year return at -22.92%, indicating it is slightly better than 3B Blackbio. Additionally, the six-month returns for 3B Blackbio, Health X Platfor, Take Solutions, Nureca, and QMS Medical are all negative.

View full answer

Should I buy, sell or hold Prevest Denpro Ltd?

30-May-2026

When is the next results date for Prevest Denpro Ltd?

22-May-2026

The next results date for Prevest Denpro Ltd is 27 May 2026.

The next results date for Prevest Denpro Ltd is scheduled for 27 May 2026.

View full answer

Are Prevest Denpro Ltd latest results good or bad?

14-Feb-2026

Prevest Denpro Ltd's Q2 FY26 results are positive, with a net profit of ₹5.54 crores, reflecting a 25.62% QoQ increase and an 18.20% rise in revenue. The company shows strong operational efficiency, but investors should be cautious of declining capital efficiency and stretched valuations.

Prevest Denpro Ltd's latest results for Q2 FY26 are quite positive. The company reported a net profit of ₹5.54 crores, which reflects a significant increase of 25.62% quarter-on-quarter (QoQ) and 14.94% year-on-year (YoY). Additionally, revenue reached ₹18.64 crores, marking an 18.20% increase QoQ and a healthy 14.57% YoY growth. <BR><BR>The operating margin also improved to 35.84%, up 211 basis points from the previous quarter, indicating effective cost management despite rising raw material and employee costs. The company's profit after tax margin expanded to 29.72%, further showcasing improved operational efficiency.<BR><BR>Overall, these results indicate strong operational momentum and profitability, positioning Prevest Denpro favorably within its sector. However, it's important to monitor the declining capital efficiency and the company's valuation, which appears stretched relative to its growth prospects.

View full answer

Is Prevest Denpro overvalued or undervalued?

04-Dec-2025

As of December 3, 2025, Prevest Denpro is considered overvalued with a valuation grade of expensive, a PE ratio of 27.29, and a year-to-date return of -24.41%, underperforming against the Sensex's 8.92%.

As of 3 December 2025, the valuation grade for Prevest Denpro has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 27.29, an EV to EBITDA of 19.44, and a Price to Book Value of 4.63. <BR><BR>In comparison to peers, Prevest Denpro's PE ratio is lower than that of Poly Medicure, which stands at 53.52, but higher than BPL, which is at 5.92. The PEG ratio of Prevest Denpro is 1.47, indicating that while growth is priced in, it does not justify the current valuation when compared to its peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -24.41% compared to the Sensex's 8.92%.

View full answer

How has been the historical performance of Prevest Denpro?

13-Nov-2025

Prevest Denpro's historical performance from March 2024 to March 2025 shows growth in net sales to 63.03 Cr, operating profit to 26.16 Cr, and profit after tax to 18.16 Cr, alongside an increase in cash reserves to 60.00 Cr, indicating overall positive financial trends.

Answer:<BR>The historical performance of Prevest Denpro shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Prevest Denpro reported net sales of 63.03 Cr, an increase from 56.43 Cr in the previous year. The total operating income also rose to 63.03 Cr from 56.43 Cr, with raw material costs slightly increasing to 14.08 Cr from 13.76 Cr. Total expenditure, excluding depreciation, grew to 40.94 Cr from 36.58 Cr, leading to an operating profit (PBDIT) of 26.16 Cr, up from 22.71 Cr. Profit before tax increased to 24.25 Cr from 21.43 Cr, resulting in a profit after tax of 18.16 Cr, compared to 16.14 Cr the previous year. The earnings per share improved to 15.13 from 13.45, while the operating profit margin slightly decreased to 35.05% from 35.18%. The profit after tax margin increased to 28.81% from 28.6%. On the balance sheet, shareholder's funds rose to 105.57 Cr from 88.62 Cr, with total assets increasing to 112.53 Cr from 94.82 Cr. Cash and cash equivalents at year-end improved to 60.00 Cr from 48.00 Cr, indicating a net cash inflow of 12.00 Cr compared to 9.00 Cr in the prior year. Overall, the financial performance of Prevest Denpro reflects growth in sales, profits, and cash reserves.

View full answer

Is Prevest Denpro technically bullish or bearish?

10-Nov-2025

As of November 7, 2025, the technical trend is mildly bearish, supported by bearish signals from the MACD, Dow Theory, and Bollinger Bands, despite a mildly bullish daily moving average.

As of 7 November 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly and monthly MACD and Dow Theory indicators, both indicating a bearish outlook. The Bollinger Bands also reflect a bearish sentiment on both weekly and monthly time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the overall bearish indicators. The stock has underperformed against the Sensex over multiple periods, further supporting the bearish view.

View full answer

Who are the top shareholders of the Prevest Denpro?

17-Jul-2025

The top shareholders of Prevest Denpro include Atul Modi, the largest individual shareholder with 37.52%, and a foreign institutional investor holding 0.63%. Public shareholders include Pushpa Kumari Pankaj Prasoon at 2.47%, while individual investors collectively hold 19.54%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Prevest Denpro include the promoters, with Atul Modi being the largest individual shareholder, holding 37.52% of the shares. Additionally, there is one foreign institutional investor (FII) that holds 0.63% of the shares. Among public shareholders, Pushpa Kumari Pankaj Prasoon is the highest, with a holding of 2.47%. Individual investors collectively hold 19.54% of the company. There are no pledged promoter holdings and no mutual funds currently invested in the company.

View full answer

Has Prevest Denpro declared dividend?

06-Jun-2025

Prevest Denpro Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of August 30, 2024. While the company shows mixed total returns across different periods, the dividend yield is relatively low at 0.21%.

Prevest Denpro Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 30 Aug 2024<BR><BR>Dividend Yield: 0.21%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.05%, with a dividend return of 0%, resulting in a total return of -13.05%.<BR><BR>Over the past year, the price return was 25.21%, the dividend return was 0.23%, leading to a total return of 25.44%.<BR><BR>In the 2-year period, the price return was 16.99%, the dividend return was 0.47%, culminating in a total return of 17.46%.<BR><BR>For the 3-year period, the price return stood at 60.7%, with a dividend return of 0.72%, resulting in a total return of 61.42%.<BR><BR>Over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Prevest Denpro has declared a dividend, the total returns over various periods show a mixed performance, with significant gains in the longer term but recent declines in the short term. The dividend yield remains relatively low, indicating that while dividends are being paid, they may not be a significant driver of returns for investors.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor long term growth as Net Sales has grown by an annual rate of 12.85% and Operating profit at 7.55% over the last 5 years

 
2

Flat results in Mar 26

3

With ROE of 16.4, it has a Expensive valuation with a 3.6 Price to Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 442 Cr (Micro Cap)

stock-summary
P/E

22.00

stock-summary
Industry P/E

92

stock-summary
Dividend Yield

0.27%

stock-summary
Debt Equity

-0.65

stock-summary
Return on Equity

16.42%

stock-summary
Price to Book

3.57

Revenue and Profits:
Net Sales:
19 Cr
(Quarterly Results - Mar 2026)
Net Profit:
6 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.27%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.71%
0%
-9.71%
6 Months
-23.06%
0%
-23.06%
1 Year
-24.09%
0.21%
-23.88%
2 Years
-14.04%
0.40%
-13.64%
3 Years
-14.52%
0.58%
-13.94%
4 Years
19.95%
1.03%
20.98%
5 Years
0%
0%
0.0%

Latest dividend: 1 per share ex-dividend date: Sep-03-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Compliances-Reg.24(A)-Annual Secretarial Compliance

30-May-2026 | Source : BSE

Non-Applicability of Annual Secretarial Compliance Report for the Financial year ended March 31 2026

Intimation Regarding Cancellation Of Schedule Of Analyst / Institutional Investor Meeting Under The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.

29-May-2026 | Source : BSE

This is to inform you that the Earnings conference call scheduled to be held on June 02 2026 has been cancelled due to unforeseen circumstances.

Board Meeting Intimation for Audited Financial Results Of The Company For Quarter And Financial Year Ended March 31 2026

21-May-2026 | Source : BSE

Prevest Denpro Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 inter alia to consider and approve Audited Financial Results of the Company for quarter and financial year ended March 31 2026

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Prevest Denpro Ltd has declared 10% dividend, ex-date: 03 Sep 25

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
12.85%
EBIT Growth (5y)
7.55%
EBIT to Interest (avg)
20.48
Debt to EBITDA (avg)
0.23
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.56
Tax Ratio
25.79%
Dividend Payout Ratio
6.59%
Pledged Shares
0
Institutional Holding
1.42%
ROCE (avg)
51.61%
ROE (avg)
16.81%

Valuation key factors

Factor
Value
P/E Ratio
22
Industry P/E
92
Price to Book Value
3.57
EV to EBIT
16.02
EV to EBITDA
14.72
EV to Capital Employed
8.41
EV to Sales
5.06
PEG Ratio
1.23
Dividend Yield
0.27%
ROCE (Latest)
52.47%
ROE (Latest)
16.42%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 1 FIIs (0.65%)

Promoter with highest holding

Atul Modi (37.52%)

Highest Public shareholder

Pushpa Kumari Pankaj Prasoon . (2.29%)

Individual Investors Holdings

18.62%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 2.60% vs -0.97% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 23.31% vs -14.80% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.94",
          "val2": "18.46",
          "chgp": "2.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.91",
          "val2": "5.80",
          "chgp": "19.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.82",
          "val2": "4.72",
          "chgp": "23.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.48%",
          "val2": "31.42%",
          "chgp": "5.06%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Mar 2026 is 8.69% vs 3.02% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Mar 2026 is 5.93% vs 2.90% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "37.40",
          "val2": "34.41",
          "chgp": "8.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.72",
          "val2": "11.99",
          "chgp": "6.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10.54",
          "val2": "9.95",
          "chgp": "5.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.01%",
          "val2": "34.84%",
          "chgp": "-0.83%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 18.60% vs 10.92% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 12.67% vs 14.51% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "52.87",
          "val2": "44.58",
          "chgp": "18.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "17.79",
          "val2": "15.54",
          "chgp": "14.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "14.67",
          "val2": "13.02",
          "chgp": "12.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "33.65%",
          "val2": "34.86%",
          "chgp": "-1.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 13.93% vs 11.70% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 12.83% vs 12.52% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "71.81",
          "val2": "63.03",
          "chgp": "13.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "24.71",
          "val2": "22.09",
          "chgp": "11.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "20.49",
          "val2": "18.16",
          "chgp": "12.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.41%",
          "val2": "35.05%",
          "chgp": "-0.64%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
18.94
18.46
2.60%
Operating Profit (PBDIT) excl Other Income
6.91
5.80
19.14%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
5.82
4.72
23.31%
Operating Profit Margin (Excl OI)
36.48%
31.42%
5.06%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 2.60% vs -0.97% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 23.31% vs -14.80% in Dec 2025

Half Yearly Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Sep'25
Change(%)
Net Sales
37.40
34.41
8.69%
Operating Profit (PBDIT) excl Other Income
12.72
11.99
6.09%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
10.54
9.95
5.93%
Operating Profit Margin (Excl OI)
34.01%
34.84%
-0.83%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Mar 2026 is 8.69% vs 3.02% in Sep 2025

Direction Arrows
Consolidated Net Profit

Growth in half year ended Mar 2026 is 5.93% vs 2.90% in Sep 2025

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
52.87
44.58
18.60%
Operating Profit (PBDIT) excl Other Income
17.79
15.54
14.48%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
14.67
13.02
12.67%
Operating Profit Margin (Excl OI)
33.65%
34.86%
-1.21%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 18.60% vs 10.92% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 12.67% vs 14.51% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
71.81
63.03
13.93%
Operating Profit (PBDIT) excl Other Income
24.71
22.09
11.86%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
20.49
18.16
12.83%
Operating Profit Margin (Excl OI)
34.41%
35.05%
-0.64%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 13.93% vs 11.70% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 12.83% vs 12.52% in Mar 2025

stock-summaryCompany CV
About Prevest Denpro Ltd stock-summary
stock-summary
Prevest Denpro Ltd
Micro Cap
Healthcare Services
Prevest Denpro Limited is one of the world's leading dental materials manufacturer, which was incorporated on May 05, 1999, with the Registrar of Companies, Jammu & Kashmir. The Company is primarily involved in the manufacturing of Dental Preparations. The Company develop, manufacture and market a comprehensive portfolio of dental materials for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile.
Company Coordinates stock-summary
Icon
No Company Details Available